CTIX ($1.71) It's about time to move. 8:09 am Cellceutix comments on positive FDA Advisory vote for Dalbavancin and Tedizolid; says vote 'further indicates a clearly defined regulatory pathway for antibiotic approvals' (CTIX) : 'We are pleased to see yesterday's positive FDA Advisory Committee vote for two antibiotics, dalbavancin and tedizolid, which treat Acute Bacterial Skin and Skin Structure Infections (:ABSSSI) caused by Gram-positive organisms, such as Staph aureus. Although the U.S. Food and Drug Administration (:FDA) is not bound to the recommendation of the advisory panel, if the drugs garner FDA marketing approval, the tedizolid regimen would be once a day for 6 days and the dalbavancin regimen would be one treatment during the first week with a second dose required the following week'.
Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid
News 
Market Data 
Discover 
AI
